Final  ||| S:0 E:6 ||| JJ
amended  ||| S:6 E:14 ||| JJ
safety  ||| S:14 E:21 ||| NN
assessment  ||| S:21 E:32 ||| NN
of  ||| S:32 E:35 ||| IN
hydroquinone  ||| S:35 E:48 ||| VBG
as  ||| S:48 E:51 ||| RB
used  ||| S:51 E:56 ||| VBN
in  ||| S:56 E:59 ||| IN
cosmetics  ||| S:59 E:69 ||| NNS
Hydroquinone  ||| S:69 E:82 ||| NNP
is  ||| S:82 E:85 ||| VBZ
an  ||| S:85 E:88 ||| DT
aromatic  ||| S:88 E:97 ||| JJ
compound  ||| S:97 E:106 ||| NN
that  ||| S:106 E:111 ||| IN
functions  ||| S:111 E:121 ||| NNS
in  ||| S:121 E:124 ||| IN
cosmetics  ||| S:124 E:134 ||| NNS
as  ||| S:134 E:137 ||| IN
an  ||| S:137 E:140 ||| DT
antioxidant ||| S:140 E:151 ||| NN
,  ||| S:151 E:153 ||| ,
fragrance ||| S:153 E:162 ||| NN
,  ||| S:162 E:164 ||| ,
reducing  ||| S:164 E:173 ||| VBG
agent ||| S:173 E:178 ||| NN
,  ||| S:178 E:180 ||| ,
or  ||| S:180 E:183 ||| CC
polymerization  ||| S:183 E:198 ||| JJ
inhibitor ||| S:198 E:207 ||| NN
.  ||| S:207 E:209 ||| .
Hydroquinone  ||| S:209 E:222 ||| NNP
is  ||| S:222 E:225 ||| VBZ
also  ||| S:225 E:230 ||| RB
used  ||| S:230 E:235 ||| VBN
as  ||| S:235 E:238 ||| IN
a  ||| S:238 E:240 ||| DT
skin  ||| S:240 E:245 ||| NN
bleaching  ||| S:245 E:255 ||| NN
agent ||| S:255 E:260 ||| NN
.  ||| S:260 E:262 ||| .
Safety  ||| S:262 E:269 ||| NNP
and  ||| S:269 E:273 ||| CC
toxicity  ||| S:273 E:282 ||| JJ
information  ||| S:282 E:294 ||| NN
indicate  ||| S:294 E:303 ||| VBP
that  ||| S:303 E:308 ||| DT
hydroquinone  ||| S:308 E:321 ||| NN
is  ||| S:321 E:324 ||| VBZ
dermally  ||| S:324 E:333 ||| VBN
absorbed  ||| S:333 E:342 ||| VBN
in  ||| S:342 E:345 ||| IN
humans  ||| S:345 E:352 ||| NNS
from  ||| S:352 E:357 ||| IN
both  ||| S:357 E:362 ||| DT
aqueous  ||| S:362 E:370 ||| NN
and  ||| S:370 E:374 ||| CC
alcoholic  ||| S:374 E:384 ||| JJ
formulations  ||| S:384 E:397 ||| NNS
and  ||| S:397 E:401 ||| CC
is  ||| S:401 E:404 ||| VBZ
excreted  ||| S:404 E:413 ||| VBN
mainly  ||| S:413 E:420 ||| RB
as  ||| S:420 E:423 ||| IN
the  ||| S:423 E:427 ||| DT
glucuronide  ||| S:427 E:439 ||| NN
or  ||| S:439 E:442 ||| CC
sulfate  ||| S:442 E:450 ||| JJ
conjugates ||| S:450 E:460 ||| NN
.  ||| S:460 E:462 ||| .
Hydroquinone  ||| S:462 E:475 ||| NNP
is  ||| S:475 E:478 ||| VBZ
associated  ||| S:478 E:489 ||| VBN
with  ||| S:489 E:494 ||| IN
altered  ||| S:494 E:502 ||| JJ
immune  ||| S:502 E:509 ||| JJ
function  ||| S:509 E:518 ||| NN
in  ||| S:518 E:521 ||| IN
vitro  ||| S:521 E:527 ||| NN
and  ||| S:527 E:531 ||| CC
in  ||| S:531 E:534 ||| IN
vivo  ||| S:534 E:539 ||| NN
in  ||| S:539 E:542 ||| IN
animals  ||| S:542 E:550 ||| NNS
and  ||| S:550 E:554 ||| CC
an  ||| S:554 E:557 ||| DT
increased  ||| S:557 E:567 ||| JJ
incidence  ||| S:567 E:577 ||| NN
of  ||| S:577 E:580 ||| IN
renal  ||| S:580 E:586 ||| JJ
tubule  ||| S:586 E:593 ||| JJ
cell  ||| S:593 E:598 ||| NN
tumors  ||| S:598 E:605 ||| NNS
and  ||| S:605 E:609 ||| CC
leukemia  ||| S:609 E:618 ||| NN
in  ||| S:618 E:621 ||| IN
F344  ||| S:621 E:626 ||| CD
rats ||| S:626 E:630 ||| NNS
,  ||| S:630 E:632 ||| ,
but  ||| S:632 E:636 ||| CC
the  ||| S:636 E:640 ||| DT
relevance  ||| S:640 E:650 ||| NN
to  ||| S:650 E:653 ||| TO
humans  ||| S:653 E:660 ||| NNS
is  ||| S:660 E:663 ||| VBZ
uncertain ||| S:663 E:672 ||| JJ
.  ||| S:672 E:674 ||| .
Quantitatively ||| S:674 E:688 ||| NNP
,  ||| S:688 E:690 ||| ,
however ||| S:690 E:697 ||| RB
,  ||| S:697 E:699 ||| ,
the  ||| S:699 E:703 ||| DT
use  ||| S:703 E:707 ||| NN
of  ||| S:707 E:710 ||| IN
hydroquinone  ||| S:710 E:723 ||| NN
in  ||| S:723 E:726 ||| IN
cosmetics  ||| S:726 E:736 ||| NNS
is  ||| S:736 E:739 ||| VBZ
unlikely  ||| S:739 E:748 ||| JJ
to  ||| S:748 E:751 ||| TO
result  ||| S:751 E:758 ||| VB
in  ||| S:758 E:761 ||| IN
renal  ||| S:761 E:767 ||| JJ
neoplasia  ||| S:767 E:777 ||| NN
through  ||| S:777 E:785 ||| IN
this  ||| S:785 E:790 ||| DT
mode  ||| S:790 E:795 ||| NN
of  ||| S:795 E:798 ||| IN
action ||| S:798 E:804 ||| NN
.  ||| S:804 E:806 ||| .
Thus ||| S:806 E:810 ||| RB
,  ||| S:810 E:812 ||| ,
hydroquinone  ||| S:812 E:825 ||| NN
is  ||| S:825 E:828 ||| VBZ
safe  ||| S:828 E:833 ||| JJ
at  ||| S:833 E:836 ||| IN
concentrations  ||| S:836 E:851 ||| NNS
of  ||| S:851 E:854 ||| IN
â‰¤1 ||| S:854 E:856 ||| CD
%  ||| S:856 E:858 ||| NN
in  ||| S:858 E:861 ||| IN
hair  ||| S:861 E:866 ||| NN
dyes  ||| S:866 E:871 ||| NNS
and  ||| S:871 E:875 ||| CC
is  ||| S:875 E:878 ||| VBZ
safe  ||| S:878 E:883 ||| JJ
for  ||| S:883 E:887 ||| IN
use  ||| S:887 E:891 ||| NN
in  ||| S:891 E:894 ||| IN
nail  ||| S:894 E:899 ||| JJ
adhesives ||| S:899 E:908 ||| NNS
.  ||| S:908 E:910 ||| .
Hydroquinone  ||| S:910 E:923 ||| NNP
should  ||| S:923 E:930 ||| MD
not  ||| S:930 E:934 ||| RB
be  ||| S:934 E:937 ||| VB
used  ||| S:937 E:942 ||| VBN
in  ||| S:942 E:945 ||| IN
other  ||| S:945 E:951 ||| JJ
leave-on  ||| S:951 E:960 ||| JJ
cosmetics ||| S:960 E:969 ||| NNS
.  ||| S:969 E:971 ||| .
